Seres therapeutics announces positive topline results from ser-109 phase 3 ecospor iii study in recurrent c. difficile infection

Ser-109 met phase 3 primary endpoint, showing highly statistically significant 30.2% absolute reduction in the rate of c. diff infection recurrence.

MCRB Ratings Summary

MCRB Quant Ranking